| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
- olodaterol
-
- $50.00
-
2025-06-20
- CAS:868049-49-4
- Min. Order: 1KG
- Purity: 0.99
- Supply Ability: 10000
- Olodaterol
-
- $15.00
-
2021-07-13
- CAS:868049-49-4
- Min. Order: 1KG
- Purity: 99%+ HPLC
- Olodaterol
-
- $15.00
-
2021-07-10
- CAS:868049-49-4
- Min. Order: 1KG
- Purity: 99%+ HPLC
|
| | Olodaterol Basic information |
| Product Name: | Olodaterol | | Synonyms: | 6-Hydroxy-8-[(1R)-1-hydroxy-2-[[2-(4-methoxyphenyl)-1,1-dimethylethyl]amino]ethyl]-2H-1,4-benzoxazin-3(4H)-one;2H-1,4-Benzoxazin-3(4H)-one, 6-hydroxy-8-[(1R)-1-hydroxy-2-[[2-(4-methoxyphenyl)-1,1-dimethylethyl]amino]ethyl]-;BI 1744(Olodaterol;Striverdi Respimat);BI-1744;Striverdi;Olodaterol, 98%, a long acting β2-adrenoceptor agonist;Olodaterol | | CAS: | 868049-49-4 | | MF: | C21H26N2O5 | | MW: | 386.44 | | EINECS: | 813-858-3 | | Product Categories: | | | Mol File: | 868049-49-4.mol |  |
| | Olodaterol Chemical Properties |
| Boiling point | 649.0±55.0 °C(Predicted) | | density | 1.250 | | solubility | DMF: 20 mg/ml; DMF:PBS (pH 7.2) (1:3): 0.25 mg/ml; DMSO: 15 mg/ml; Ethanol: 1 mg/ml | | form | A crystalline solid | | pka | 9.42±0.20(Predicted) | | color | Light yellow to khaki | | Stability: | Hygroscopic |
| | Olodaterol Usage And Synthesis |
| Description | In 2013, olodaterol (also known BI-1744 CL) was approved for the treatment of chronic obstructive pulmonary disease (COPD) in Russia (March), Canada (June), and the EuropeanUnion (October). Olodaterol is delivered via the Respimat Soft Mist inhaler. Olodaterol was discovered from an effort to identify a β2-adrenergic receptor agonist that could be given once daily and with a superior safety profile over known β2- adrenergic receptor agonists. Olodaterol is a potent β2 agonist (EC50=0.1 nM, intrinsic activity=88%) and is highly selective for the β2 receptor over β1 and β3 receptors. In preclinical models in guinea pigs and dogs, olodaterol had a rapid onset of action and provided bronchoprotection over 24 h. Mechanistic studies indicated that olodaterol forms a highly stable complex with the β2-adrenergic receptor, with a dissociation half-life of 17.8 h. The synthesis of olodaterol proceeds through an (R)-styrene epoxide that is prepared via enantioselective reduction of an α-chloroketone intermediate. Ring opening of the epoxide with 1-(4- methoxyphenyl)-2-methylpropan-2-amine provides olodaterol. | | Originator | Boehringer-Ingelheim (European Union) | | Uses | Olodaterol-d3 is labelled Olodaterol (O262000) which is a long acting b-adrenoceptor agonist used as an inhalation for treating patients with chronic obstructive pulmonary disease (COPD). | | Definition | ChEBI: A member of the class of benzoxazine that is 6-hydroxy-1,4-benzoxazin-3-one in which the hydrogen at position 4 is replaced by a (1R)-1-hydroxy-2-{[1-(4-methoxyphenyl)-2-methylpropan-2-yl]amino}ethyl group. Used (as its hydrochloride salt)
for long-term treatment of airflow obstruction in patients with chronic obstructive pulmonary disease including chronic bronchitis and/or emphysema. | | Brand name | Striverdi | | Synthesis | Synthesis of Olodaterol:2,5-dihydroxyacetophenone (2) was reacted with benzyl bromide to give 1-[2-hydroxy-5-(benzyloxy)-phenyl]ethanone (3), which was reduced to 1-[2-hydroxy-3-amino-5-(benzyloxy)phenyl]-acetophenone (5) by nitration reaction in the presence of platinum dioxide, and then by acylation, intramolecular condensation, and bromination to give 6-benzyloxy-8-( 2-bromoacetyl)-2H-benzo[b][1,4]-oxazin-3(4H)-one (7), 7 underwent asymmetric reduction and intramolecular cycloaddition to give (R)-6-benzyloxy-8-(oxiranyl-2-yl)-2H-benzo[b][1,4]oxazin-3(4H)-one (8), and 8 was condensed with 1-(4-methoxyphenyl)-2-methyl-2-propanamine (9) to give 6 -Benzyloxy-8-[(1R)-1-hydroxy-2-[[2-(4-methoxyphenyl)-1,1-dimethylethyl]amino]ethyl]-2H-benzo[b][1,4]oxazin-3(4H)-one (10), and then de-benzyl-protected to give 1 in a total yield of 16.2% (in 2). The platinum dioxide used in this method is more expensive, and the bromination reaction yield is lower (74%). (ii) Compound 2 was benzylated, nitrated, nitro-reduced, chlorinated, intramolecularly condensed, oxidized, esterified, condensed and debenzyl protected to obtain Olodaterol. The target product obtained by this method was the racemate of Olodaterol, which was not a single-configuration target product. |
| | Olodaterol Preparation Products And Raw materials |
|